RenovoRx (Nasdaq: RNXT)

RenovoRx (Nasdaq: RNXT) is a life sciences company developing novel precision oncology therapies based on a local drug delivery platform for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRxs patented Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform is designed to ensure precise therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapys toxicities versus systemic intravenous therapy. RenovoRxs novel and patented approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Its Phase III lead product candidate is a novel oncology drug-device combination product. It is being investigated under a U.S. investigational new drug application that is regulated by the FDAs 21 CFR 312 pathway. The investigational drug-device combination candidate utilizes RenovoCath, the Companys FDA-cleared drug-de...